KZR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	562 506
Average Volume	777 488
Market Cap	57.51M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.330 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-15	Schiller Mark C.	Sell	0	Common Stock
2024-01-15	Schiller Mark C.	Sell	165 000	Employee Stock Option (right to buy)
2024-01-15	Schiller Mark C.	Sell	250 000	Employee Stock Option (right to buy)
2024-01-07	Belsky Marc	Buy	295 000	Employee Stock Option (right to buy)
2024-01-07	Mordwinkin Nicholas Michael	Buy	275 000	Employee Stock Option (right to buy)

INSIDER POWER
-14.22
Last 100 transactions
Buy: 7 465 931 \| Sell: 10 295 837

Volume Correlation

Long: -0.08 (neutral)

Short: 0.66 (moderate)

Signal:(32.232) Neutral

Kezar Life Sciences Inc Correlation

10 Most Positive Correlations
CMLS	0.976
AROW	0.974
ESSA	0.973
BSRR	0.973
ISTR	0.973
AADI	0.972
CPTN	0.972
MOFG	0.972
BCBP	0.972
CBAN	0.969

10 Most Negative Correlations
SGEN	-0.959
TZPS	-0.957
RPHM	-0.954
LMB	-0.95
PESI	-0.944
MLAI	-0.941
RAM	-0.941
GPACU	-0.939
COCO	-0.939
AMPH	-0.938

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kezar Life Sciences Inc Correlation - Currency/Commodity

0.00
( neutral )

Kezar Life Sciences Inc Financials

Annual	2023
Revenue:	$7.00M
Gross Profit:	$5.93M (84.77 %)
EPS:	$-1.400

Q4	2023
Revenue:	$0
Gross Profit:	$-280 000 (0.00 %)
EPS:	$-0.440

Q3	2023
Revenue:	$7.00M
Gross Profit:	$6.72M (96.03 %)
EPS:	$-0.320

Q2	2023
Revenue:	$0
Gross Profit:	$-249 000 (0.00 %)
EPS:	$-0.340

Financial Reports:

No articles found.

Kezar Life Sciences Inc

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.